Tesaglitazar is primarily used in the treatment of type 2 diabetes. It functions as a dual agonist of peroxisome proliferator-activated receptors (PPAR) alpha and gamma, which helps in improving insulin sensitivity and regulating blood glucose levels. This makes it effective in managing hyperglycemia in diabetic patients. Additionally, Tesaglitazar has shown potential in improving lipid profiles by reducing triglycerides and increasing HDL cholesterol, which can be beneficial for patients with dyslipidemia. Its dual action on PPAR receptors also suggests a possible role in addressing metabolic syndrome, although further research is needed to confirm its efficacy in this area.